4DMedical Advances Innovation in Lung Imaging

4DMedical Limited (ASX: 4DX), a pioneer in advanced lung imaging, has bolstered its financial footing while advancing clinical outcomes. The company received AU$6.0 million in R&D Tax Incentive credits, bringing its pro forma cash balance to AU$22.9 million as of June 30, 2025. With a potential AU$22.7 million capital boost from option exercises, alongside an AU$10 million strategic investment from Pro Medicus, 4DMedical is well placed to advance the rollout of its CT:VQ™ solution.

From a clinical perspective, the company marked a milestone as its XV LVAS® technology was featured in the American Journal of Respiratory and Critical Care Medicine, highlighting its impact in advancing COPD treatment. The study demonstrated XV LVAS®’s ability to accurately predict life-threatening pneumothorax complications in COPD patients undergoing bronchoscopic lung volume reduction. This innovation offers physicians actionable insights to improve patient outcomes and reduce health system burdens. Through AI-driven imaging solutions delivered via SaaS, 4DMedical continues to transform global respiratory care

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com